Laidlaw’s James Ahern Named to Crain’s New York Notable Leaders in Finance 2024
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
Laidlaw served as Co-Manager on the $129,000,000 Common Stock and Concurrent Private Placement for Soleno Therapeutics (SLNO)
Laidlaw served as Co-Manager on the $129,000,000 Common Stock and Concurrent Private Placement for Soleno Therapeutics (SLNO)
Laidlaw acts as Co-Manager on the $287,500,000 Follow-On Offering for Viking Therapeutics.
Laidlaw is pleased to act as Co-Manager on Vikings 287.5mm dollar offering. Laidlaw Capital Markets was the Sole Book Runner on Viking’s 27.6mm dollar IPO in 2015. VKTX is now over a one Read More...
Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
On December 14, 2022, NLS Pharmaceutics (NASDAQ:NLSP,)(NASDAQ:NLSPW) announced the closing of its previously publicized purchase agreement with BVF Partners L.P. ("BVF") comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), Read More...
Laidlaw acts as Sole Placement Agent on the $4,000,000 NLS Pharmaceutics Ltd. Private Placement
Laidlaw is pleased to have acted as the Sole Placement Agent on the $4,000,000 Private Placement for NLS Pharmaceutics. Read Article
Stay In Touch